Pediatric Nephrology

, Volume 22, Issue 7, pp 981–986

Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy

  • David Askenazi
  • Barry Myones
  • Ankur Kamdar
  • Robert Warren
  • Maria Perez
  • Marietta De Guzman
  • Anna Minta
  • M. John Hicks
  • Arundhati Kale
Original Article

DOI: 10.1007/s00467-007-0447-9

Cite this article as:
Askenazi, D., Myones, B., Kamdar, A. et al. Pediatr Nephrol (2007) 22: 981. doi:10.1007/s00467-007-0447-9

Abstract

Outcomes in children with proliferate lupus nephritis (PLN) show 9–15% progress to end-stage renal disease (ESRD) at 5 years. Immunosuppression improves outcome, but significant side effects are possible. Clinical and laboratory analyses are poor predictors of class and progression in PLN. We describe 28 patients with systemic lupus erythematosus (SLE), between 1990 and 2005, whose initial biopsy (Bx1) showed PLN and who received nine monthly doses of intravenously administered cyclophosphamide (CYP) (500–750 mg/m2 up to 1 g to maintain their absolute neutrophil count (ANC) > 3,000). Continued therapy with additional quarterly intravenous (i.v). administration of CYP was dictated by repeat renal biopsy (Bx2). Bx1 was done 1 ± 1.6 years after diagnosis of SLE. Bx2 showed histological improvement by WHO classification in 20/25 children; 3/25 were unchanged, 1/25 was categorized as new class V, and 1/25 was worse. Four patients (14%) had infectious complications requiring hospitalization (one of these died). Mean follow-up (f/u) after Bx2 was 3.5 ± 2.3 years. At last follow-up, 26 patients had normal glomerular filtration rate (GFR), with a mean of 126 ± 42.8 ml/min per 1.73 m2 body surface area, one non-compliant patient had ESRD, and one had chronic renal failure. At last follow-up, most patients had minimal to no proteinuria. Clinical and biopsy results greatly improved after 9 monthly intravenously administered CYP pulses in most children with class IV PLN. Those who did not improve are at risk for flares and progression of disease. The tailoring of therapies based on findings from a biopsy after induction may improve outcomes.

Keywords

Lupus nephritis Proliferative Protocol biopsy Cyclophosphamide Outcome 

Copyright information

© IPNA 2007

Authors and Affiliations

  • David Askenazi
    • 1
  • Barry Myones
    • 2
  • Ankur Kamdar
    • 2
  • Robert Warren
    • 2
  • Maria Perez
    • 2
  • Marietta De Guzman
    • 2
  • Anna Minta
    • 2
  • M. John Hicks
    • 3
  • Arundhati Kale
    • 2
  1. 1.Department of PediatricsUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Pediatric RheumatologyTexas Children’s HospitalHoustonUSA
  3. 3.Department of PathologyBaylor College of MedicineHoustonUSA

Personalised recommendations